Friday, July 31, 2026 · Covering: Mon–Fri this week
TL;DR
Two large strategic deals defined the week: Intercontinental Exchange is buying bond-trading platform MarketAxess for ~$6B, and Grant Thornton is acquiring CBIZ for a $5B enterprise value — the largest US accounting-firm deal in 25 years. The Fed held rates at 3.50–3.75% for a fifth straight meeting, but the 9–3 vote (three officials wanted a hike) signals a genuinely divided committee. And Big Tech split the market in two: Microsoft soared ~15% on a 43% Azure growth surge while Meta fell ~9% on a soft outlook and collapsing free cash flow — a live referendum on which AI spenders are actually earning a return.
TOP 3 DEALS
DEAL 01
Financial Institutions / Market Structure
EQUITY VALUE~$6B ($167/share cash, 33% premium)
STRUCTUREAll-cash; close 1H 2027 pending approvals
BUY-SIDE ADVISORSBofA Securities (Sullivan & Cromwell; Morgan Lewis — legal)
SELL-SIDE ADVISORSJ.P. Morgan (Weil Gotshal — legal)
ICE — which owns the NYSE — is buying MarketAxess, the leading electronic marketplace for trading corporate bonds. Bond trading has been slower to move onto screens than stocks, so ICE is paying up to own that shift and bolt fixed-income trading onto its data-and-exchange empire. Bond Buyer ↗
Why it matters for recruiting: Exchanges and trading platforms are prized because they're toll-road businesses — they take a small fee on enormous volume, with high margins and recurring revenue. A 33% premium tells you ICE sees strategic scarcity: there are very few scaled electronic bond venues to buy. Good talking point on how consolidation in market structure feeds the sell-side's own economics, and a clean bulge-bracket-vs-bulge-bracket advisory matchup (BofA vs. JPM).
DEAL 02
Business / Professional Services
ENTERPRISE VALUE~$5B ($55.00/share cash)
STRUCTUREAll-cash, PE-backed (New Mountain Capital); close Q4 2026
BUY-SIDE ADVISORSDeutsche Bank (lead)
SELL-SIDE ADVISORSGoldman Sachs
Grant Thornton is buying CBIZ, a provider of accounting, tax and benefits services, to become the fifth-largest US professional-services firm — the biggest deal of its kind in over 25 years. The check is backed by New Mountain Capital, reflecting the wave of private-equity money now flowing into accounting firms. INSIDE Public Accounting ↗
Why it matters for recruiting: This is the visible edge of a real trend — PE rolling up accounting and professional-services firms, drawn by sticky, recurring client relationships and fragmented ownership. It's a great "what's a theme you're watching" answer. Note the structure too: a partnership-style firm being consolidated with sponsor capital raises tricky questions about how you value and finance a business whose main asset is its people.
DEAL 03
Healthcare / Bioprocessing
ENTERPRISE VALUE~$1.5B ($31/share; ~24% premium)
STRUCTURECash-and-stock (36% cash / 64% stock); close Q4 2026
BUY-SIDE ADVISORSPerella Weinberg; Goldman Sachs
SELL-SIDE ADVISORSCenterview Partners
Repligen, which supplies the tools and materials used to manufacture biologic drugs, is buying BioLife Solutions for its biopreservation media — the specialized fluids that keep cell and gene therapies alive during freezing and transport. It's a bolt-on to deepen Repligen's position in one of pharma's fastest-growing manufacturing niches. GeekWire ↗
Why it matters for recruiting: A clean cash-and-stock consideration example with an exact split (36/64) — be ready to explain why a buyer mixes the two: cash gives sellers certainty, stock preserves the buyer's balance sheet and lets sellers share in the upside (and defers their tax). Also a good illustration of "picks-and-shovels" investing — Repligen sells to every drugmaker rather than betting on one drug, which the market rewards with a premium multiple.
SECTOR SIGNAL
DEFENSE / AEROSPACE
Quiet week for big A&D M&A, but the theme rolls on: PMGC's A&B Aerospace signed a multi-year supply agreement with Precision Aerospace & Defense — more of the supply-chain locking behind this year's deals. GlobeNewswire ↗
TECH / TMT
Bloomberg is set to acquire Canoe Intelligence and Hg is selling a majority stake in Quantios — private-markets data and software keep consolidating as the plumbing behind alternatives scales up. AltAssets ↗
INDUSTRIALS
LXP Industrial Trust agreed to a ~$5.2B take-private by Brookfield and CPP Investments — infrastructure and pension capital continuing to buy hard, cash-generative real assets off the public market. Dealroom ↗
LEVERAGED FINANCE
Bain Capital and Tillman committed $1.5B to Eaton Fiber — private capital continuing to pour into digital infrastructure, one of the most active levered-buildout themes of 2026. Intellizence ↗
M&A / MARKET STRUCTURE
The through-line of the week is strategics buying platforms with recurring, fee-based revenue — ICE/MarketAxess in trading, Grant Thornton/CBIZ in professional services, Repligen/BioLife in bioprocessing tools. With the Fed on hold and financing markets open, corporates are using strong balance sheets to buy annuity-like cash flows rather than chase cyclical growth. It's a defensive posture dressed up as offense — worth naming as the dominant deal logic of mid-2026. CNBC ↗
MARKET TONE
Fed holds, but splits. The FOMC kept rates at 3.50–3.75% for a fifth straight meeting on a 9–3 vote — three officials (Hammack, Kashkari, Logan) wanted a hike, an unusually large dissent. CNBC ↗
Microsoft vs. Meta = the AI trade in miniature. Microsoft jumped ~15% (Azure +43%, first fiscal year above $100B) while Meta fell ~9% on soft guidance and a 91% drop in quarterly free cash flow. The market is now paying for AI returns, not AI spending. Motley Fool ↗
Growth is cooling. Q2 GDP came in at 1.5%, below expectations — soft enough to keep the Fed's hold defensible but not a recession signal.
Deal financing stays wide open. Two all-cash deals of $5B+ (ICE, Grant Thornton) in one week underscore how available capital is for strategic buyers with strong balance sheets.
Watch the dissenters. A 3-vote hawkish dissent is the loudest internal disagreement in months; if inflation firms on higher oil, the "hold through year-end" consensus could crack.
INTERVIEW ANGLE
TOPIC: WHY BUYERS PAY PREMIUMS FOR "RECURRING REVENUE"
All three of this week's top deals are the same idea in different sectors: a strategic buyer paying a healthy premium for a business with sticky, fee-based, recurring revenue. Understanding why that revenue is worth more is one of the most useful valuation instincts you can show.
Here's the frame:
Recurring revenue lowers risk, which lowers the discount rate. A trading platform (MarketAxess) or an accounting firm (CBIZ) earns predictable fees year after year. Predictable cash flows are discounted at a lower rate in a DCF, which mechanically raises the valuation.
It commands a higher multiple. That's why software and exchanges trade at premium EV/EBITDA multiples versus a cyclical manufacturer — investors pay up for cash flows they can count on.
Premiums reflect scarcity, not just synergies. ICE paid 33% over market because scaled electronic bond venues barely exist. When a strategic asset is nearly impossible to replicate, the premium is a control-and-scarcity premium as much as a synergy story.
The counterpoint. "Recurring" isn't "guaranteed" — Meta's 91% free-cash-flow collapse this week is a reminder that even great franchises can see cash flow evaporate when they over-invest. Naming that keeps you honest.
How to bring it up: "The ICE–MarketAxess deal is a clean example of why recurring, fee-based revenue earns a premium — ICE paid 33% over market for a bond-trading platform because that fee stream is predictable and there are almost no scaled alternatives to buy. Predictable cash flows get a lower discount rate and a higher multiple, so the premium is really paying for certainty and scarcity." (This connects directly to the DCF and comps mechanics you'll be tested on — a strong way to show you think about valuation drivers, not just formulas.)